Neuronetics Names Todd Cushman as Vice President, Business Development
June 01 2021 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced today that Todd Cushman will
join the company as Vice President, Business Development, effective
immediately. Mr. Cushman will be responsible for international
strategy and Company commercial operations, including contract
manufacturing, field service and technical support. Anthony Pui,
Vice President, International Commercial Development, will report
to Mr. Cushman in his new role.
“Todd’s appointment is a key step in our company’s growth, and
I’m proud to have him on board,” said Keith J. Sullivan, President
and CEO of Neuronetics. “His industry knowledge and extensive
leadership experience across product development and global
operations make him an asset to the team in expanding access to
NeuroStar® Advanced Therapy for Mental Health and pursuing our
mission to transform patient lives. There’s no telling what else we
will accomplish with him at the helm of Neuronetics’ business
development strategy.”
Mr. Cushman brings more than 35 years of industry experience to
the Company. Before joining Neuronetics, he was a founding member
of Bioness, Inc., a medical technology company specializing in
neurological rehabilitation and implantable products for pain
management and held several leadership roles throughout his tenure
– including president and CEO from 2013 to 2021. Prior, he held
leadership positions at Medtronic, Inc., Acumed Medical Equipment,
Inc., and American Hospital Supply Corp. Inc. (now Baxter, Inc.).
He graduated from Brown University with a Bachelor of Arts and
earned his Master of Business Administration from the Marshall
School of Business at the University of Southern California. Mr.
Cushman currently serves on the Boards of Directors for Voiceitt
and the Alfred Mann Institute for Biomedical Development at the
Technion, Israel Institute of Technology.
“I’m excited to join Neuronetics at such a crucial moment in the
fight against depression and mental health conditions,” said
Cushman. “The Company has an impressive reputation as a leader in
the depression treatment space, and I look forward to lending my
experience to build upon its growth and help drive market
innovation to meet patients’ needs.”
About NeuroneticsNeuronetics,
Inc. is a commercial-stage medical technology company focused on
designing, developing, and marketing products that improve the
quality of life for patients who suffer from psychiatric disorders.
Its commercial product, NeuroStar Advanced Therapy for Mental
Health, is a non-invasive and non-systemic office-based treatment
that uses transcranial magnetic stimulation, or TMS, to create a
pulsed, MRI-strength magnetic field that induces electrical
currents designed to stimulate specific areas of the brain
associated with mood. The system is cleared by the United States
Food and Drug Administration, or FDA, for the treatment of major
depressive disorder in adult patients who have failed to achieve
satisfactory improvement from prior antidepressant medication in
the current episode. Visit neurostar.com for safety information and
indications for use. NeuroStar is also available in other parts of
the world, including Japan, where it is listed under Japan’s
national health insurance. Additional information can be found at
www.neuronetics.com.
Media Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024